

1/41

(B) EFFECT OF HEPARIN ON THE AFFINITY OF  $\alpha$ -THROMBIN FOR FIBRIN

| HEPARIN ( $\mu$ M) | Kd ( $\mu$ M) |
|--------------------|---------------|
| 0                  | 3.22          |
| 0.1                | 0.25          |
| 0.25               | 0.15          |
| 1                  | 0.79          |
| 20                 | 4.26          |






Fig. 1


2/41

*Fig. 2*

3/41

*Fig. 3*


4/41





*Fig. 4*

20/2220" 52E6FOOT

5/41

*Fig. 5*

*Fig. 6A**Fig. 6B*

204220 "SEE FOOT"






Fig. 7

8/41

*Fig. 8*



9/41

*Fig. 9*

10/41




*Fig. 10*

Fig. 11



11/41

fig. 12





12/41

10019325.022702

10/019325

13/41


*Fig. 13*

20220526T00T

14/41

|     | LMWH | V21  |      |      |
|-----|------|------|------|------|
| 0   | 21   | 21   | 0    | 0    |
| 0.5 | 24.7 | 23.1 | 12.4 | 1.12 |
| 1   | 24.3 | 30.7 | 2.37 | 10.1 |
| 1.5 | 39.4 | 52.1 | 2.98 | 2.31 |


Comparative effects of V21 and LMWH on APTT

*Fig. 14*

15/41


| LMWH | V21 | lmwhse | V21 se |      |
|------|-----|--------|--------|------|
| 0    | 0   | 0      | 0      | 0    |
| 0.5  | 1.1 | 0.8    | 0.19   | 0.32 |
| 1    | 2.8 | 1.5    | 0.91   | 0.32 |
| 1.5  | 2.6 | 2.8    | 0.06   | 0.36 |

Comparative effects of LMWH and V21 on the anti-Xa level

*Fig. 15*

16/41

# Schematic Diagram of the Procedure




*Fig. 16*



17/41

Fig. 17

Modified Wessler Model ( V-21) Clot Weight (%)




Treatment Groups

18/41

|     | LMWH | V21  |     |     |
|-----|------|------|-----|-----|
| 0   | 37.8 | 37.8 | 3.7 | 3.7 |
| 0.5 | 9.6  | 18   | 4.7 | 6.1 |
| 1   | 7.5  | 5.6  | 2.1 | 2.6 |
| 1.5 | 9.1  | 1.7  | 8.2 | 0.6 |

Comparison of LMWH and V21: Prophylaxis model

*Fig. 18*

19/41

Comparison of LMWH and V21:Prophylaxis model





Fig. 19

20/41

Fig. 20


Modified Wessler Model ( V-21) Clot Radioactivity (%)



21/41

|     | LMWH | V21 | se  | se  |
|-----|------|-----|-----|-----|
| 0   | 30   | 30  | 8   | 8   |
| 0.5 | 12   | 18  | 3.8 | 7.8 |
| 1   | 11   | 5   | 1.7 | 2.1 |
| 1.5 | 4.5  | 1.6 | 4.2 | 0.7 |

Comparison of LMWH and V21: Prophylaxis Model

*Fig. 21*

22/41

Comparison of LMWH and V21: Prophylaxis Model




fig. 22

23/41

20/2220" SEE FIG. 23

Comparison of LMWH and V21 in Treatment Model





Fig. 23

24/41

|   | LMWH | V21 |     |     |
|---|------|-----|-----|-----|
| 0 | 242  | 242 | 104 | 104 |
| 1 | 155  | 137 | 37  | 30  |
| 3 | 129  | 21  | 52  | 31  |

Comparison of LMWH and V21 in Treatment Model

*Fig. 24*



25/41

LMWH and V21 on Thrombus Accretion





fig. 25

26/41


|   | LMWH | V21 |     |     |
|---|------|-----|-----|-----|
| 0 | 282  | 282 | 111 | 111 |
| 1 | 202  | 174 | 37  | 29  |
| 3 | 174  | 57  | 51  | 20  |

LMWH and V21 on Thrombus Accretion

*Fig. 26*

27/41

# V21 Treatment of DVT in Chronic Rabbit Model Clot Accretion



28/41

V21 Treatment of DVT in Chronic Rabbit Model % Change in Clot Weight





Fig. 28

202220 "SECRET"


29/41



- 6000 MWH 130899
- 6000 MWH 130899 + Fm
- ▼ 8050 MWH 200899
- ▽ 8050 MWH 200899 + Fm
- 10350 MWH 010399
- 10350 MWH 010399 + Fm
- ▲ Unfractionated heparin
- △ Unfractionated heparin + Fm

*Fig. 29*

30/41



- 5600 MWH 42168-1
- 5600 MWH 42168-1 + Fm
- ▼ 8200 MWH 42164-1B
- ▽ 8200 MWH 42164-1B + Fm
- 10300 MWH 42164-1A
- 10300 MWH 42164-1A + Fm
- ▲ Unfractionated heparin
- △ Unfractionated heparin + Fm

Fig. 30

31/41








Fig. 31

32/41


*Fig. 32*




33/41

*Fig. 33*


34/41

*Fig. 34*

35/41

*Fig. 35*


36/41

*Fig. 36*

37/41

*fig. 37*

202220" SEE FOOT



38/41

20/220" SECT 100T





fig. 38

39/41


Fig. 39



40/41

*Fig. 40*

204220" 5261001





41/41




fig. 41